GoodRx Holdings (GDRX) Shares Outstanding (Weighted Average) (2019 - 2026)

GoodRx Holdings has disclosed Shares Outstanding (Weighted Average) across 8 years of filings, most recently posting $340.5 million for Q1 2026.

• Shares Outstanding (Weighted Average) for Q1 2026 came in at $340.5 million, down 10.2% year-over-year; the trailing twelve-month figure through Mar 2026 was $340.5 million (down 10.2% YoY), and the FY2025 annual result was $356.3 million, down 7.62% from the prior year.
• Shares Outstanding (Weighted Average) came in at $340.5 million for Q1 2026 at GoodRx Holdings, down from $356.3 million in the prior quarter.
• In the past five years, Shares Outstanding (Weighted Average) ranged from a high of $414.7 million in Q1 2022 to a low of $340.5 million in Q1 2026.
• The 5-year median for Shares Outstanding (Weighted Average) is $390.0 million (2024), against an average of $390.6 million.
• Across the five-year window, Shares Outstanding (Weighted Average) increased 2.11% in 2022 and slipped 10.2% in 2026, its largest moves.
• GoodRx Holdings' Shares Outstanding (Weighted Average) stood at $412.9 million in 2022, then decreased by 0.62% to $410.3 million in 2023, then retreated by 5.99% to $385.7 million in 2024, then declined by 7.62% to $356.3 million in 2025, then dropped by 4.43% to $340.5 million in 2026.
• The last three Shares Outstanding (Weighted Average) figures came in at $340.5 million (Q1 2026), $356.3 million (Q4 2025), and $346.8 million (Q3 2025), per Business Quant data.